Rapid Development of the FDA ACMT COVID-19 ToxIC (FACT) Pharmacovigilance Pilot Project to Monitor Adverse Events Reported in Association with COVID-19 Therapeutics
Saved in:
| Published in | Toxicology letters Vol. 350; p. S20 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier B.V
01.09.2021
Published by Elsevier B.V. Published by Elsevier B.V |
| Online Access | Get full text |
Cover
Loading…
| Author | Aldy, K. Wax, P.M. Brent, J. |
|---|---|
| Author_xml | – sequence: 1 givenname: P.M. surname: Wax fullname: Wax, P.M. organization: American College of Medical Toxicology, Phoenix, USA – sequence: 2 givenname: K. surname: Aldy fullname: Aldy, K. organization: American College of Medical Toxicology, Phoenix, USA – sequence: 3 givenname: J. surname: Brent fullname: Brent, J. organization: University of Colorado, Denver, USA |
| BookMark | eNqFkc9u1DAQhy1UJLaFR0DysT2ktZ1_jpBAUbYLK7XqqixcLceeNK6ycWS7gb4PD4q7iyrg0tMcZn7fjOY7RkejHQGh95ScU0KLi68kLXmSsTI7ZfSMEMZJQl6hBeVllaS0qI7Q4nnkDTr2_p4QUmRFvkC_buVkNF7CDIOddjAGbDscesCrZY3r5nqLm5vv62VCK7y1P9cNPl3VzfYMb3rpdlLZ2dyZQY4K8MYMNuCNs_egAg4WX9vRBOtwrWdwHvDlHPEe38JkXQCNzYhr760yMhg74h8m9H8t68HJCR6CUf4tet3JwcO7P_UEfVtdbpsvydXN53VTXyWK5QVJqCKtUlBqmgHjHWmzXFWSQ1nkHZSclVqXTOZUUah0q1nLqUpblldtrJx06Qn6eOBOD-0OtIrnOjmIyZmddI_CSiP-7YymF3d2FjwraMnTCMgPAOWs9w665ywl4smV2LsSTyIEo2LvSpCY-_BfTpmw_0pcY4YX058OaYi_mQ044ZWBqEQbF1UIbc0LhN9zh7Fo |
| CitedBy_id | crossref_primary_10_1007_s40265_023_01981_7 crossref_primary_10_1007_s13181_023_00961_3 |
| ContentType | Journal Article |
| Copyright | 2021 Published by Elsevier B.V. Copyright © 2021 Published by Elsevier B.V. Published by Elsevier B.V. All rights reserved. 2021 Published by Elsevier B.V. |
| Copyright_xml | – notice: 2021 Published by Elsevier B.V. – notice: Copyright © 2021 Published by Elsevier B.V. Published by Elsevier B.V. All rights reserved. 2021 Published by Elsevier B.V. |
| CorporateAuthor | On behalf of the Toxicology Investigators Consortium FACT Study Group |
| CorporateAuthor_xml | – name: On behalf of the Toxicology Investigators Consortium FACT Study Group |
| DBID | AAYXX CITATION 5PM |
| DOI | 10.1016/S0378-4274(21)00280-0 |
| DatabaseName | CrossRef PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-3169 |
| EndPage | S20 |
| ExternalDocumentID | PMC8461783 10_1016_S0378_4274_21_00280_0 S0378427421002800 |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29Q 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXUO ABEFU ABFNM ABFRF ABFYP ABJNI ABLST ABMAC ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AFFNX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHEUO AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AKIFW ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLECG BLXMC CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KCYFY KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SPCBC SPT SSJ SSP SSZ T5K WH7 WUQ XPP ZGI ZXP ~G- ~KM AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION SSH 5PM EFKBS |
| ID | FETCH-LOGICAL-c2560-1c0bcce7d14e28f0b45c9a8e765fe7827dd72a51c1e9dbd2b81c3b259b1c380f3 |
| IEDL.DBID | .~1 |
| ISSN | 0378-4274 |
| IngestDate | Thu Aug 21 18:33:00 EDT 2025 Thu Apr 24 23:03:16 EDT 2025 Tue Jul 01 01:04:02 EDT 2025 Fri Feb 23 02:43:53 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2560-1c0bcce7d14e28f0b45c9a8e765fe7827dd72a51c1e9dbd2b81c3b259b1c380f3 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8461783 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8461783 crossref_primary_10_1016_S0378_4274_21_00280_0 crossref_citationtrail_10_1016_S0378_4274_21_00280_0 elsevier_sciencedirect_doi_10_1016_S0378_4274_21_00280_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2021 2021-09-00 20210901 |
| PublicationDateYYYYMMDD | 2021-09-01 |
| PublicationDate_xml | – month: 09 year: 2021 text: September 2021 |
| PublicationDecade | 2020 |
| PublicationTitle | Toxicology letters |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V Published by Elsevier B.V. Published by Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V – name: Published by Elsevier B.V. Published by Elsevier B.V |
| SSID | ssj0006465 |
| Score | 2.3438876 |
| SourceID | pubmedcentral crossref elsevier |
| SourceType | Open Access Repository Enrichment Source Index Database Publisher |
| StartPage | S20 |
| Title | Rapid Development of the FDA ACMT COVID-19 ToxIC (FACT) Pharmacovigilance Pilot Project to Monitor Adverse Events Reported in Association with COVID-19 Therapeutics |
| URI | https://dx.doi.org/10.1016/S0378-4274(21)00280-0 https://pubmed.ncbi.nlm.nih.gov/PMC8461783 |
| Volume | 350 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pa9swFBaluwzG2LqNdevKO5TSQt1ItmzZR-M2JBvtwuaO3owkK50h2KFJx3rZX9M_tPrhxM6hFHYyyNaT7ff09En63hNCByJiWGBuCE888SiPdJ8Tke5XTJfyhEtm83RfXEajK_r1OrzeQtkqFsbQKlvf73y69dZtyaD9m4N5VQ1-4oDF1Ow0Ers_aObtlDJj5af_OppHRO1xkuZhzzzdRfE4CbbwyCfHVoiHnxqfNimTvTFo-Aa9bsEjpO793qItVe-gw4nLPn1_AnkXTLU4gUOYdHmp73fQK7dEBy7y6B16-MHnVQk92hA0U9CAEIZnKaTZRQ7Z91_jM48kkDd_xxkcDdMsP16L_VPdVDNjNTCpZs0SJm5VB5YNOFdxC_a854WCc0OrXICD-6qEqoaeYYBZDe411vuM9-hqeJ5nI689tMGTBj15RGIhpWIlocqPp1jQUCY8ViwKp0rDEVaWzOchkUQlpSh9ERMZCD0JE_oa42nwAW3XTa0-IuDaEWuZCSVEUKaURjYylFj6kQx4EPi7iK5UVcg2o7k5WGNWdNQ1reHCaLjwSWE1XOBddLquNncpPZ6rEK_soNiwzUIPO89VZRt2s27QZPXevFNXv212bw0ICYuDT__f6Gf00jfMG8uE20Pby9s79UVDp6XYt31jH71Ix99Gl4-uOhKs |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELem7gEkhMYAMRhwD2japIXaiRMnj1G2qmVrqSBDe4tsx4VIVVKtBbHvwwfFf9I2fUCTeIrk5M5J7nw-23e_Q-iDiBgWmJuAJ554lEd6zIlIjyumW3nCJbM43eNJNLyhn27D2z2UrXNhTFhla_udTbfWum3pt3-zv6iq_lccsJiak0Zizwf1un3foFOFPbSfjq6Gk41BjqitKGme9wzBNpHHMbGNpz45s3w8_K8pajdqsjMNDQ7Q09Z_hNS94jO0p-pDdDJ1ANT355Bv86mW53AC0y009f0heuJ26cAlHz1Hf77wRVVCJ3IImhlonxAGFymk2TiH7PO30YVHEsib36MMTgdplp9t2P6qvldzozgwrebNCqZuYwdWDThrcQe25PNSwaWJrFyC8_hVCVUNHd0AsyHc6azzGS_QzeAyz4ZeW7fBk8aB8ojEQkrFSkKVH8-woKFMeKxYFM6U9khYWTKfh0QSlZSi9EVMZCD0Okzoa4xnwUvUq5tavULAtS3WPBNKiKBMKe3cyFBi6Ucy4EHgHyG6FlUhW1BzU1tjXmyj17SECyPhwieFlXCBj9DHDdnCoXo8RBCv9aDYUc9CzzwPkbIdvdl0aIC9d-_U1Q8L8K19QsLi4PX_d_oePRrm4-viejS5eoMe-yYQxwbGHaPe6u6neqs9qZV4146UvxZCFV0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rapid+Development+of+the+FDA+ACMT+COVID-19+ToxIC+%28FACT%29+Pharmacovigilance+Pilot+Project+to+Monitor+Adverse+Events+Reported+in+Association+with+COVID-19+Therapeutics&rft.jtitle=Toxicology+letters&rft.au=Wax%2C+P.M.&rft.au=Aldy%2C+K.&rft.au=Brent%2C+J.&rft.date=2021-09-01&rft.pub=Elsevier+B.V&rft.issn=0378-4274&rft.eissn=1879-3169&rft.volume=350&rft.spage=S20&rft.epage=S20&rft_id=info:doi/10.1016%2FS0378-4274%2821%2900280-0&rft.externalDocID=S0378427421002800 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-4274&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-4274&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-4274&client=summon |